International Stem Cell Corp Subsidiary Lifeline Skin Care Announces Entry Into Chinese Market

CARLSBAD, CA--(Marketwire - Sep 6, 2012) - International Stem Cell Corporation (OTCQB: ISCO) ( ("ISCO" or "the Company"), a California-based biotechnology company, today announced that its cosmoseutical subsidiary Lifeline Skin Care ( has entered an agreement to distribute its anti-aging skin care products in China using the extended clinical network of one of the largest pharmaceutical companies in China, Sinopharm Group.

Lifeline develops, manufactures and commercializes advanced skin care products based on growth factors and peptides derived from human parthenogenetic stem cells. The products, developed by ISCO's scientific team in collaboration with renowned skin care experts, deliver anti-aging benefits, resulting in healthier- and younger-looking skin. The products are available for purchase through medical offices and luxury spas across the United States and from

Sales of cosmetic products in mainland China, with its large population of affluent consumers and surging demand for consumer products, are estimated at approximately $8 billion / year. With an annual growth rate of over 10%, the Chinese market for beauty products represents an enormous growth opportunity for Lifeline Skin Care. Together with our Chinese partner Brilliant Sunrise SBC, which is responsible for importation and regulatory approvals, Lifeline will offer its breakthrough anti-aging skin care products in China's largest and most respected hospitals, spas and through online channels.

"We're excited to partner with the Lifeline Skin Care brand of science-based skin care and to bring their cutting edge technology to China. Lifeline is a leader in an emerging field that will change how serious cosmetic brands approach skin care. By rolling out the products in channels such as Shanghai's 9th People Hospital and Hua Shan Hospital, which have some of the best cosmetic surgery and skin care centers in China, we aim to introduce the product in a way that highlights Lifeline Skin Care's unique value proposition," said Nicole Sha, Co-founder of Brilliant Sunrise SBC.

"We are extremely pleased that we can now offer our stem cell-based anti-aging skin care products in China. By using this network of healthcare centers and spas, we are making our unique products available to consumers through a credible provider that they already trust and have a relationship with," said Donna Queen, President of Lifeline Skin Care.

About International Stem Cell Corporation

International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs) hence avoiding ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenetic, homozygous stem cell line that can be a source of therapeutic cells for hundreds of millions of individuals of differing genders, ages and racial backgrounds with minimal immune rejection after transplantation. hpSCs offer the potential to create the first true stem cell bank, UniStemCell™. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology (, and stem cell-based skin care products through its subsidiary Lifeline Skin Care ( More information is available at

To receive ongoing corporate communications via email, visit:

To like our Facebook page or follow us on Twitter for company updates and industry related news, visit: and

Safe harbor statement

Statements pertaining to anticipated developments, potential sales growth, expectations regarding new distribution channels and other opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects" or "estimates") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products and the management of collaborations, regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update forward-looking statements.

Contact Information:


International Stem Cell Corporation
Dr. Simon Craw
Executive Vice President
Phone: 760-940-6383

Investor Relations:
MZ Group
Mark McPartland
Senior Vice President
Phone: 212-301-7130